Outcomes in Breast Cancer Patients Who Refuse Recommended Therapy

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.